Clinical trial
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced…
NCT00193297 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193297 |
|---|---|
| Title | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma |
| Official title | A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovary Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Paclitaxel, Carboplatin |
| Enrollment | 50 |
| Start date | Feb 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: